| 培美曲塞联合铂类对比吉西他滨联合铂类治疗晚期非小细胞肺癌的meta分析 |
| Alternative Title | A meta-analysis of pemetrexed plus platinum chemotherapy versus gemcitabine plus platinum chemotherapy for advanced non-small cell lung cancer
|
| 姜金; 李伦; 王晓晶; 田金徽; 王权; 林乔 |
| 2011-01-20
|
| Source Publication | 中国肺癌杂志
Impact Factor & Quartile |
| ISSN | 1999-6187
|
| Volume | 14Issue:1Pages:43-48 |
| Abstract | 背景与目的培美曲塞联合铂类方案(PP方案)作为晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)一线化疗方案的疗效是否优于吉西他滨联合铂类方案(GP方案),目前尚无定论。本研究旨在评价采用PP方案与GP方案治疗晚期NSCLC的疗效及安全性。方法计算机检索Pubmed、EMBASE、Cochrane Library、中国期刊全文数据库、中国生物医学文献数据库、中文科技期刊全文数据库等,同时追查纳入文献的参考文献,纳入PP方案对比GP方案治疗晚期NSCLC的随机对照试验(randomized controlled trial,RCT)。根据Cochrane Han... |
| Other Abstract | BACKGROUND AND OBJECTIVE: Whether pemetrexed plus platinum (PP) regimen is superior to gemcitabine plus platinum (GP) regimen for patients with advanced non-small cell lung cancer (NSCLC) is unclear. The aim of this study is to evaluate the efficacy and safety of PP versus GP regimens for patients with NSCLC.METHODS: We searched relevant randomized controlled trials (RCTs) from Pubmed, EMBASE, Cochrane Library, Chinese Journal Full-text Database, Chinese Biomedical Literature Database, Chinese Scientific Journals Full-text Database, and traced the related references to obtain the information that has not been found. We made quality assessment of qualified RCTs assessed by the exclusion and inclusion criteria and used RevMan 5.0 provided by the Cochrane Collaboration to perform meta-analysis.RESULTS: Four RCTs involving 2,235 patients were identified. There were no statistical differences between PP and GP regimens in one-year survival rate (OR=1.09, 95%CI: 0.91-1.29), the efficiency of disease (OR=1.00, 95%CI: 0.40-2.52), but overall survival (MD=0.26, 95%CI: 0.21-0.30), alopecia (OR=0.51, 95%CI: 0.39-0.66) and hematologic toxicity were significantly different.CONCLUSIONS: The clinical efficiency of PP and GP regimens for advanced NSCLC was similar, but the side effects were different. The toxicity of PP regimen has the tendency to be more tolerable. |
| Keyword | 培美曲塞
吉西他滨
铂类
肺肿瘤
|
| Subject Area | Pharmacology & Pharmacy
; Respiratory System
; Biochemistry & Molecular Biology
; Demography
|
| DOI | 10.3779/j.issn.1009-3419.2011.01.09
|
| Publication Place | TIANJIN
|
| Indexed By | PubMed
; MEDLINE
|
| Language | 中文
|
| First Inst | 是
|
| Funding Project | 兰州大学教学研究项目
|
| Host of Journal | 中国抗癌协会
; 中国防痨协会
; 天津医科大学总医院
|
| Project Number | 兰州大学2010教学研究项目(No.201022)、兰州大学循证医学中心循证医学创新项目(No.2010LDEBM-B)资助~~
|
| Funding Organization | LZU
|
| PMID | 21219831
|
| IRID | CNKI:0047056
|
| Department | 兰州大学循证医学中心兰州大学基础医学院;兰州大学第二临床医学院;兰州大学第一临床医学院 |
| Citation statistics |
|
| Document Type | 期刊论文
|
| Identifier | https://ir.lzu.edu.cn/handle/262010/163585
|
| Collection | 基础医学院
|
Recommended Citation
GB/T 7714 |
姜金,李伦,王晓晶,等. 培美曲塞联合铂类对比吉西他滨联合铂类治疗晚期非小细胞肺癌的meta分析[J].
中国肺癌杂志,2011,14(1):43-48.
|
| APA |
姜金,李伦,王晓晶,田金徽,王权,&林乔.(2011).培美曲塞联合铂类对比吉西他滨联合铂类治疗晚期非小细胞肺癌的meta分析.中国肺癌杂志,14(1),43-48.
|
| MLA |
姜金,et al."培美曲塞联合铂类对比吉西他滨联合铂类治疗晚期非小细胞肺癌的meta分析".中国肺癌杂志 14.1(2011):43-48.
|
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.
